Department of Molecular Medicine & Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1005, New Zealand.
Sci Rep. 2013;3:1661. doi: 10.1038/srep01661.
Here we describe an entirely new class of cell-penetrating peptide (CPP) represented by the short peptide Xentry (LCLRPVG) derived from an N-terminal region of the X-protein of the hepatitis B virus. Xentry permeates adherent cells using syndecan-4 as a portal for entry, and is uniquely restricted from entering syndecan-deficient, non-adherent cells, such as resting blood cells. Intravenous injection of Xentry alone or conjugated to β-galactosidase led to its delivery to most tissues in mice, except circulating blood cells. There was a predilection for uptake by epithelia. Anti-B-raf antibodies and siRNAs linked to Xentry were capable of killing B-raf-dependent melanoma cells. Xentry represents a new class of CPP with properties that are potentially advantageous for life science and therapeutic applications.
在这里，我们描述了一类全新的细胞穿透肽（CPP），其代表是源自乙型肝炎病毒 X 蛋白 N 端区域的短肽 Xentry（LCLRPVG）。Xentry 通过 syndecan-4 作为进入的门户穿透贴壁细胞，并且独特地被限制进入 syndecan 缺陷的非贴壁细胞，例如静止血细胞。单独注射 Xentry 或与β-半乳糖苷酶缀合的 Xentry 可将其递送至小鼠的大多数组织，除了循环血细胞。上皮细胞优先摄取。与 Xentry 连接的抗 B-raf 抗体和 siRNA 能够杀死依赖 B-raf 的黑色素瘤细胞。Xentry 代表了一类具有潜在优势的新型 CPP，可用于生命科学和治疗应用。
